Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | GRB2 | P62993 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6885441 | 0.86 | SNCA (0.56) | SNCAHIF1AALDH1A1NPC1RAB9A | |
| Bromide SCHEMBL1840962 | 0.86 | SNCA (0.56) | SNCAHIF1AALDH1A1NPC1RAB9A | |
| Bromide SCHEMBL7028089 | 0.83 | SNCA (0.57) | SNCAHIF1AHSD11B1ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL9419870 | 0.82 | SNCA (0.53) | SNCAHIF1AALDH1A1NPC1RAB9A | |
| Bromide SCHEMBL39844 | 0.81 | SNCA (0.73) | SNCAHIF1AALDH1A1CYP3A4APP | |
| Hydrochloric Acid SCHEMBL2446696 | 0.77 | SNCA (0.69) | SNCAHIF1AALDH1A1CYP3A4APP | |
| Bromide SCHEMBL163158 | 0.77 | SNCA (0.67) | SNCAHIF1AALDH1A1APPCPA1 | |
| Iodide SCHEMBL9321342 | 0.77 | SNCA (0.69) | SNCAHIF1AALDH1A1CYP3A4APP | |
| Bromide SCHEMBL1503289 | 0.76 | SNCA (0.61) | SNCAHIF1AALDH1A1CYP3A4RAB9A | |
| Bromide SCHEMBL2447513 | 0.76 | SNCA (0.61) | SNCAHIF1AALDH1A1CYP3A4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110698408-B | Antiviral drug for treatment of arenavirus infection | 奇尼塔病毒性出血热有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-110776453-A | Antiviral drug for treatment of arenavirus infection | 奇尼塔四有限责任公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-110698408-A | Antiviral drug for treatment of arenavirus infection | 奇尼塔四有限责任公司 | 2020-01-17 | — | — | CN | disclosed |
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | KINETA VIRAL HEMORRHAGIC FEVER, LLC (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Kineta Four, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9498470-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | EIF2AK2, ZC3HAV1, SARS1 | SNCA 1980/4885HIF1A 2689/4885PTPN1 4164/4885 |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | SNCA 1980/4885HIF1A 2689/4885PTPN1 4164/4885 |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | SNCA 1980/4885HIF1A 2689/4885PTPN1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.